Aptorum Group Ltd. (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets, marketed under the brand name NativusWell®. For more information, visit the company’s website at www.aptorumgroup.com
To register for The Wall Street Investor Forum and watch the live presentation, visit http://ibn.fm/TWSIFRegistration
To view IBN’s virtual coverage of The Wall Street Investor Forum, visit https://ibn.fm/TWSIF
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at The Wall Street Investor Forum. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of next month’s The Wall Street Investor Forum.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations in 2020, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
